LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Public ClinicalTrials.gov record NCT00144872. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Evaluation of Lamotrigine in Subjects With Absence Seizures
Study identification
- NCT ID
- NCT00144872
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 54 participants
Conditions and interventions
Conditions
Interventions
- Lamotrigine Drug
Drug
Eligibility (public fields only)
- Age range
- Up to 12 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2004
- Primary completion
- Apr 21, 2006
- Completion
- Apr 21, 2006
- Last update posted
- Sep 28, 2017
2004 – 2006
United States locations
- U.S. sites
- 23
- U.S. states
- 13
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | San Jose | California | 95128 | — |
| GSK Investigational Site | Loxahatchee Groves | Florida | 33470 | — |
| GSK Investigational Site | Melbourne | Florida | 32901 | — |
| GSK Investigational Site | Panama City | Florida | 32405 | — |
| GSK Investigational Site | Tallahassee | Florida | 32308 | — |
| GSK Investigational Site | Tampa | Florida | 33607-6350 | — |
| GSK Investigational Site | Atlanta | Georgia | 30342 | — |
| GSK Investigational Site | Louisville | Kentucky | 40202 | — |
| GSK Investigational Site | Springfield | Missouri | 65804 | — |
| GSK Investigational Site | Newark | New Jersey | 07103 | — |
| GSK Investigational Site | Buffalo | New York | 14222 | — |
| GSK Investigational Site | Rochester | New York | 14642 | — |
| GSK Investigational Site | Chapel Hill | North Carolina | 27599-7600 | — |
| GSK Investigational Site | Greenville | North Carolina | 27834 | — |
| GSK Investigational Site | Raleigh | North Carolina | 27607 | — |
| GSK Investigational Site | Portland | Oregon | 97239 | — |
| GSK Investigational Site | Germantown | Tennessee | 38138 | — |
| GSK Investigational Site | Nashville | Tennessee | 37212 | — |
| GSK Investigational Site | Fort Worth | Texas | 76104 | — |
| GSK Investigational Site | Seattle | Washington | 98105 | — |
| GSK Investigational Site | Madison | Wisconsin | 53792 | — |
| GSK Investigational Site | Milwaukee | Wisconsin | 53215 | — |
| GSK Investigational Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00144872, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 28, 2017 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00144872 live on ClinicalTrials.gov.